ing to and sequestering transcription factors such as The cyclin-dependent kinase (CDK) inhibitor p18 E2F that regulate S-phase genes. This activity of pRb blocks progression of the cell cycle by associating with is regulated by phosphorylation events in a cell cyclethe cyclin D-dependent kinases CDK6 and CDK4. To dependent manner. Throughout the early part of G1, better understand the regulation of p18 gene expres-pRb is found in an underphosphorylated form which is sion, we isolated full-length cDNA clones from a hu-capable of associating with E2F. Phosphorylation of man BT-20 breast cancer cell cDNA library. These pRb by cyclin-CDK complexes late in G1 results in the clones were then used to isolate the human gene from release of E2F and the activation of S-phase genes. , p15  INK4b , p18  INK4c and p19 INK4d . The INK polymorphism was identified in the 3 untranslated proteins specifically bind and inhibit CDK4 and CDK6, region of BT-20 cell cDNA clones that contained the thereby preventing cyclin D-dependent phosphorylapreviously described codon 72 mutation. The codon 72 tion of pRb (6). Each INK4 protein consists of repeated mutation was also detected in 3 of 35 breast tumors ankyrin domains which presumably play a role in proanalyzed using a mismatch PCR/RFLP strategy. ᭧ 1998 tein-protein interactions (6). Inactivating mutations in p16 and p15 genes are also inactivated by chromosomal deletions or transcriptional silencing, alterations which perturb the pRb-controlled checkpoint (9, 10). On the other hand, no mutations were found in the closely The execution of the S phase of the cell cycle requires related p19 gene (11). the activity of gene products whose expression is conThe human INK4 p18 cDNA was first isolated in trolled by the retinoblastoma protein (pRb), a cell cycle 1994 (12). Alterations of the p18 gene, though less fretranscriptional regulator (1). pRb restricts gene expresquent than those affecting p16, have been observed in sion to the appropriate phases of the cell cycle by bindhuman cancer. We have isolated a mutant form of p18 from human BT-20 breast cancer cells that is defective
p16 and p15 genes are also inactivated by chromosomal deletions or transcriptional silencing, alterations which perturb the pRb-controlled checkpoint (9, 10) . On the other hand, no mutations were found in the closely The execution of the S phase of the cell cycle requires related p19 gene (11). the activity of gene products whose expression is con-
The human INK4 p18 cDNA was first isolated in trolled by the retinoblastoma protein (pRb), a cell cycle 1994 (12) . Alterations of the p18 gene, though less fretranscriptional regulator (1). pRb restricts gene expresquent than those affecting p16, have been observed in sion to the appropriate phases of the cell cycle by bindhuman cancer. We have isolated a mutant form of p18 from human BT-20 breast cancer cells that is defective 1 These authors contributed equally to this work. p18 gene were observed in three of 21 acute lympho-blastic leukemias examined and in one of 17 cases of . This amplicon multiple myeloma examined (15, 16) . Loss of heterozy-was subcloned as a BamHI/XbaI insert in the pcDNA3 plasmid vector gosity in the p18 gene was found in one case of non-and sequenced. Radiolabelled cRNA was synthesized using Sp6 RNA small-cell lung cancer (17) . Moreover, the p18 gene re-polymerase as indicated in the manufacturer's protocol (Promega Riboprobe in vitro transcription systems). Hybridization of 2 mg of sides on chromosome 1p32, a region that is disrupted in K562 polyA/ RNA with the antisense probe was performed using a variety of human cancers (12 and references therein).
the RPA II Kit (Ambion), following the supplier's protocol. Assay
To better understand the role of p18 in the control products were resolved on a 5% denaturing polyacrylamide gel and of cell proliferation and its involvement in human can-revealed by autoradiography. cer, we proceeded to clone the human p18 gene. We
Mutational analysis of p18 in breast cancer tissue. Samples rereport here the isolation of full-length p18 cDNA clones maining from 35 breast tumors after determination of hormone reas well as the structure and sequence of the human ceptor content were used for the mutational analysis. DNA fragments for mutation analysis were generated from total RNA by amplifying p18 gene and a mutational analysis of p18 in breast p18 coding nucleotides /189 to /375 by RT-PCR (Fig. 4) . The 5 cancer cell lines and tumors.
primer corresponded to nucleotides /189 to /213 and contained an A instead of a T at nucleotide 212 (5-CGATTTGAAAGACCGAAC-
MATERIALS AND METHODS
TGGTTAC-3, mismatch underlined). This substitution was designed to add an internal BstEII restriction site to p18 PCR frag-DNA and RNA isolation. The cell lines used for RNA/DNA analy-ments containing the codon 72 substitution (14) . The C-terminal olises and cDNA library preparation were obtained from the American gonucleotide was complementary to nucleotides / 375 to /353 of Type Culture Collection. BT-20 and MCF-7 human breast cancer p18 (5-GTGCTTCACCAGGAACTCCACCA-3).
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P-labeled dATP cells were maintained as described (14) . Myelogenous leukemia K562 was incorporated during the PCR which was carried out at an annealcells were maintained in RPMI 1640 medium with 10% fetal bovine ing temperature of 62 ЊC in a reaction volume of 20 ml. Half of the serum and antibiotics. Genomic DNA and total RNA was isolated PCR product was then digested with 10 units of the restriction enfrom cells using Tri-Reagent according to the manufacturer's instruczyme BstEII for 3 hours after which 10 ml of formamide loading tions. Polyadenylated RNA was isolated by two cycles of chromatog-buffer was added to each sample. A 4 ml aliquot was heat-denatured raphy on oligo-(dT)-cellulose columns (18) .
and run on an 6% denaturing polyacrylamide gel. To confirm the specificity of the PCR, the 188-bp product was purified, subcloned Characterization of full-length p18 cDNA clones. A UNI-ZAP and sequenced. cDNA library was prepared using human BT-20 breast cancer cell Direct sequencing of RT-PCR products was performed as described poly(A)
/ RNA according to the supplier's protocol (Stratagene Clon-(20) using oligonucleotides complementary to bases 114-136 and 507-ing Systems). A partial cDNA fragment comprising the coding se-483 for the PCR and an oligonucleotide complementary to nucleotides quence of the human p18 cDNA (GenBank accession number 288-266 for sequencing. U17074) was amplified from BT-20 RNA by RT-PCR and cloned into pcDNA3 vector as described (14) . To isolate full-length p18 cDNAs, this fragment was labelled with [a- Prehybridization, hybridization, and washes were performed as pre-Characterization of a Full-length p18 cDNA viously described (19) . Double-stranded DNA fragments were subcloned into pBluescript
To isolate full-length p18 cDNAs we screened a BT-II. The longest p18 cDNA was sequenced in both orientations using 20 human breast cancer cell cDNA library with a probe T7 and T3 vector primers and additional oligonucleotide primers comprised of the coding region of p18. Nine positive synthesized in our laboratory.
clones were obtained and six of these were characterIsolation of genomic p18 clones. To isolate the human p18 gene, ized in detail. The sequence of the p18 transcript is we screened a genomic human leucocyte lEMBL-3 DNA library (Clontech, Palo Alto, CA) using standard procedures (18, 19) . The shown in Figure 1 . The longest p18 cDNA isolated from purified full-length p18 cDNA fragment was labeled to high specific the BT-20 cell cDNA library, designated clone 40, con- These results indicate that the codon 72 and 114 variants are expressed from different alleles.
Characterization of the p18 Gene
The p18 gene was isolated using conventional screening techniques. Four positive clones were obtained by screening a lEMBL-3 human leukocyte genomic DNA library with a full-length p18 cDNA probe. All four clones were found to contain the entire coding sequence of the p18 gene. These clones and subclones thereof were plaque-purified for further analysis by restriction mapping and sequencing.
The p18 gene is comprised of three exons and spans greater than 7.5 kbp of genomic DNA. The first exon is noncoding and contains a 1204-nucleotide long 5- the stop codon and contains the 364 nucleotides of 3 untranslated region.
Exons 1 and 2 are separated by an intron of 458 nucleotides. Intron 1 was sequenced in its entirety (Figure 1) . Exons 2 and 3 are separated by intron 2 which sequence analysis package and the tfsites.dat database contains approximately 4500 bp, approximately 750 of identified a number of potential Sp1 binding sites. The 5 which were sequenced. The size of intron 2 was esti-kb of putative p18 promotor DNA was capable of directmated by restriction analysis of l clones and PCR am-ing the expression of the luciferase reporter gene in tranplification of genomic DNA (data not shown). To con-siently transfected cells (data not shown). firm the deduced structure of the p18 gene, Southern blot analysis of Sac I-digested l phage DNA and human Characterization of p18 mRNA genomic DNA was performed using exon-specific probes and the full-length p18 cDNA. The band pattern A previous report proposed the existence of multiple p18 transcripts (12) . Since the different p18 cDNAs that observed with the p18 probes was in agreement with the restriction map of the p18 gene (data not shown). we isolated did not vary significantly in length, we assessed the size of the p18 transcript(s) expressed in huFurthermore, the exon-specific probes detected single strongly hybridizing bands, suggesting that p18 gene man breast BT-20 cells and leukemia K-562 cells by Northern blot analysis. As illustrated in Figure 2 , the 32 Pis a single-copy gene and that highly homologous genes do not exist in the human genome.
labeled p18 cDNA detected a predominant 2.2 kb mRNA present in total RNA prepared from BT-20 and K562 The genomic clone that we isolated contains approximately 5 kb of DNA upstream of exon 1. Approximately cells. Though a few much fainter bands could be identified, the size of the major transcript is in agreement with 129 bp of 5 flanking DNA were sequenced (Fig. 1) . The putative p18 promotor did not contain a recognizable that of the longest cDNA that we isolated. Similar results were obtained using polyadenylated RNA. TATA box but the region adjoining the putative transcription start site was GC-rich. A search for the presence of To verify that the longest cDNA (clone 40) truly corresponded to the longest transcript, we performed riboknown transcription factor binding sites using the FIND-PATTERNS function of the Wisconsin GCG Version 9.0 nuclease protection assays (RPA) using polyadenylated 018 and /41 relative to the 5 end of the longest cDNA we isolated. The most abundant start site mapped to approximately /17 relative to the 5 end of cDNA clone 40. In addition, a sixth start site was detected around /92 relative to the 5 end of cDNA clone 40. Rapid amplification of cDNA ends yielded products with 5 ends in the vicinity of the /17 and /92 start sites (data not shown). Taken together, the results of the RPA and Northern analysis indicate that transcription of the p18 mRNA initiates in the vicinity of the 5 end of cDNA clone 40.
Analysis of p18 Status in Human Breast Tumors
We previously reported the existence of an inactivating mutation of p18 in BT-20 breast cancer cells (14) . Preliminary results obtained in tumor specimens using SSCP analysis suggested that this p18 variant might occur frequently in breast tumors. We therefore designed a sensitive mismatch PCR/restriction fragment length polymorphism assay to detect the codon 72 variant. Radiolabelled DNA fragments were generated by RT-PCR from a second series of 35 breast tumors using a 5 oligonucleotide primer that was designed to introduce a BstEII site in fragments harboring the codon 72 substitution (Fig. 4A ). Following digestion with BstE II, p18 PCR products containing the codon 72 variant are cleaved to a 167-bp fragment. This assay allowed us to detect both the codon 72 and codon 114 substitutions simultaneously since the codon 114 polymorphism introduces a BstE II site in the p18 sequence which generates a 157-bp fragment following digestion of the corresponding RT-PCR product with BstE II. The BstEII restriction fragments were resolved from the nondigested 188-bp PCR product on polyacrylamide gels. fragments. The BstEII restriction fragment correfilm for 5 days. The undigested probe (Lane 1) was exposed to film sponding to the codon 72 substitution was detected in overnight in this composite figure. three of the 35 breast tumor RNA samples examined (Tumor nos. 2, 3 and 4). These results were confirmed by direct sequencing of PCR products amplified by RT-PCR of tumors 2, 3 and 4 (Fig. 4C) . The existence of the codon 72 substitution was also confirmed in DNA mRNA from K562 cells which express higher levels of p18 mRNA (Fig. 2) . A cRNA probe was generated from samples from 2 positive tumors for which DNA samples were available. All three tumors also expressed the coa genomic p18 fragment comprised of 129 bp of 5 flanking DNA contiguous with 170 bp of the 5 end of don 114 polymorphism (Fig. 4B) . On the other hand, tumor no. 1 contained wild-type p18 mRNA only exon 1. As shown in Figure 3 , this probe detected a group of 5 start sites clustered between approximately whereas both the codon 114 variant and wild-type p18 FIG. 4 . Analysis of p18 status in human breast tumors. A, Schematic diagram depicting the mismatch PCR/RFLP assay for the p18 variants at coding nucleotides 214 and 342. The arrows designated P1 and P2 correspond to the upstream and downstream primers used to generate the full-length PCR product (188 bp). The upstream primer (incorporating a single mismatch at nucleotide 212) lies 2 nucleotides 5 to codon 72 sequences. The presence of a C at nucleotide 214 (codon 72 variant) associated with the mismatched nucleotide at position 212 creates a BstEII restriction site thereby generating a fragment of 167 bp after BstEII digestion of the corresponding PCR product. The C to T change at nucleotide 342 (codon 114 variant) creates a natural BstEII restriction site to generate a fragment of 157 bp following digestion. B, PCR products before (0) and following (/) BstEII digestion. The wild type p18 cDNA (WT) as well as MCF-7 genomic DNA and RT-PCR products were used as negative controls whereas the p18 codon 72 variant cDNA as well as BT-20 genomic DNA and RT-PCR products were used as positive controls. BstEII digests of PCR amplicons from 5 unrelated breast tumor RNA (RT) and, where indicated, their corresponding genomic DNA (DNA), are shown. Restriction fragment length analysis of the PCR products after digestion with BstEII was performed on a denaturing 6% polyacrylamide gel. C, Direct sequencing of p18 RT-PCR amplification products from MCF-7 cells and human breast tumors #2, 3 and 4.
were detected in tumor no. 5 (Fig. 4B) . The silent poly-restriction fragment was detected in MCF-7 cell samples that were intercalated between tumor samples and morphism at codon 114 was detected in 26 (74%) of the 35 tumors analyzed. In contrast, neither BstEII processed concurrently (Fig. 4B and data not shown) .
ants. This modification of an established technique DISCUSSION should prove useful in similar applications. The results obtained by Northern blot analysis using We report here the structure and sequence of the gene encoding the human cyclin-dependent kinase in-total as well as polyadenylated RNA isolated from BT-20 and K-562 cells indicate that the most abundant hibitor p18. The p18 gene consists of three exons, the first of which is entirely noncoding. Exons 1 and 2 are p18 transcript expressed in these cells is approximately 2.2 kb long. The size of the major transcript approxiseparated by a relatively short 0.45 kb intron whereas exons 2 and 3 are separated by approximately 4.5 kb. mates that of the longest cDNA that we isolated from BT-20 cells and transcription start sites in the vicinity We have sequenced the entire p18 gene with the exception of 3.7 kb in intron 2. The sequence of the genomic of the 5 end of the cloned cDNA were identified by ribonuclease protection assay. The 2.2 kb transcript DNA and the deduced structure of the p18 gene were in agreement with the sequence of the longest cDNA likely corresponds to the 2.4 kb message observed in an RNA blot prepared from normal human tissues (26) . clone that we isolated from a human BT-20 breast cancer cell cDNA library.
Normal tissues were also found to express a 1.2 kb transcript that we have not detected in K562 and BTThe INK4c gene is a member of the cyclin D-dependent kinase inhibitor family which is comprised of p16/ 20 cells. Depending on the cDNA probe used, up to 5 p18 transcripts have been identified in normal tissues INK4a, p15/INK4b, p19/INK4d and p18. The importance of the INK4a gene in human cancer has been well (12) . Other investigators have identified p18 transcripts of 1.5 and 0.7 kb in breast cancer cells but no established, particularly in familial melanoma (21). Moreover, disruption of the INK4a locus in mice led to 2.2-2.4 kb mRNA (27) . Such differences in the expression pattern of p18 transcripts may be attributable to the development of spontaneous tumors such as sarcomas and lymphomas (22) . These results indicate that cell-specific expression patterns, differences between normal and cancerous tissue and/or differences in INK4a plays a major role as a regulator of retinoblastoma protein function in mice, at least in the affected probe selection and hybridization conditions.
The levels of p18 mRNA are regulated in a cell cyclecell lineages. This also signifies that INK4 functions are not totally redundant in all cells. However, the role of dependent manner. In murine macrophages stimulated with CSF-1, p18 mRNA levels peak in S phase, as do the other INK4 genes in human cancer is not as well understood. We identified a mutant form of p18 in BT-p19 mRNA levels (28). These induction kinetics are similar to that of p16b in human lymphocytes stimu-20 human breast cancer cells that abrogates the ability of p18 to bind CDK6 (14) . This mutation, which was lated with phytohemaglutinin and IL-2 (29). However, in human leukemic HL-60 cells, treatment with phororiginally identified by SSCP analysis and direct sequencing of RT-PCR products from BT-20 cells, was con-bol esters caused a decrease in p18 and p19 mRNA and an increase in p15 mRNA (30). In addition, p18 is firmed by the isolation of full-length cDNA clones harboring the codon 72 substitution (this report).
induced during myogenic and B cell differentiation (31, 32). It will be of interest to characterize the human p18 Using a mismatch PCR/RFLP assay, we have identified this p18 variant in three of 35 breast tumors exam-promotor and study its regulation by various regulators of cell growth. The availability of the human p18 gene ined. The occurrence of the same mutation in different individuals suggests that the codon 72 variant may will allow more detailed studies of the control of p18 expression in both normal and cancerous cells, and will be a polymorphism. However, more detailed genetic studies will be required to confirm this possibility. It allow further studies into the involvement of p18 in human cancer. is also of interest to note that the codon 114 substitution was identified in approximately 75% of the tumors examined. This polymorphic site was detected in 19% ACKNOWLEDGMENTS of 31 healthy Caucasian volunteers (23) and in 17% of 71 lung cancer specimens (24). The higher incidence
The authors wish to thank D. Monté and J. Simard for helpful discussions, P. Couture for tips on the RFLP analysis, F. Labrie for observed in our series may be attributed to characterishis interest in this work, and the Illustration Service of our research tics of the sample population which was composed of center for artwork. This work was supported by a grant from the residents of Québec province.
Canadian Breast Cancer Research Initiative to C. L. Additional supMismatch PCR/RFLP strategies that have been de-port was provided by Endorecherche. C. L. was supported in part by scribed in the literature usually utilize non-radioactive a fellowship from the Fonds de la recherche en santé du Québec. DNA and agarose gel electrophoresis. To enhance the sensitivity of this technique and to augment the resolu-REFERENCES tion between different restriction fragments, we have used radiolabelled DNA and polyacrylamide gels (25). allowing the simultaneous detection of two p18 vari-
